I have a couple of questions. So, you mentioned very strong demand outlook in India as well as in the Middle East region. Can you comment on the US and the European regions demand conditions and whether we are in a position to address that market?
What would be the expected CAPEX budget for FY25?
I just wanted to check what was the revenues from the COVID molecule in the same quarter last year which you are referring to as a high base?
The previous management had indicated that the COVID revenues in year FY22 was Rs.120 crore. So, this was a bit of a surprise that in FY23 there was no COVID revenues as such. So, are you saying that there are no revenues in the Q3 FY23 for COVID because you are referring to the nine month s number as a year -to-date figure?